Soleno Therapeutics Shares Slide 13% Premarket After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment
Soleno Therapeutics宣佈美國FDA將遺傳性疾病治療的審查期延長後,盤前股價下跌13%
Soleno Therapeutics Shares Slide 13% Premarket After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment
Soleno Therapeutics宣佈美國FDA將遺傳性疾病治療的審查期延長後,盤前股價下跌13%
譯文內容由第三人軟體翻譯。
使用瀏覽器的分享功能,分享給你的好友吧